Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Curaleaf Holdings Inc (OP:CURLF)

1.440 +0.017 (+1.19%)
Streaming Delayed Price Updated: 1:31 PM EDT, Aug 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Curaleaf Holdings Inc

< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
420 with CNW — Germany’s Growing Marijuana Industry Holds its Breath as Elections Loom
Via CannabisNewsWire
Topics Cannabis
420 with CNW — Pain Increases Odds of Cancer Patients Using Marijuana, Tobacco
Via Investor Brand Network
Topics Cannabis
420 with CNW — Pain Increases Odds of Cancer Patients Using Marijuana, Tobacco
Via CannabisNewsWire
Topics Cannabis
Cannabis Stock Valuations Reflect No Expectation Of Federal Reform: Study
Viridian Capital's latest report shows cannabis stocks pricing in no rescheduling or 280E relief, leaving MSOs stuck in valuation limbo. 
Via Benzinga
Topics Cannabis
420 with CNW — New Hampshire House Committee Discusses Measure to Legalize Recreational Cannabis
Via CannabisNewsWire
Topics Cannabis
Grön Launches New Edibles Flavors Across Curaleaf Dispensaries In Arizona
 
Via Benzinga
420 with CNW — President Trump to Play Pivotal Role in Marijuana Policy Reform and Rescheduling
Via CannabisNewsWire
Topics Cannabis Government
420 with CNW — Data Shows After Ohio Legalized Marijuana, Fatal Car Crashes Have Dropped
Via CannabisNewsWire
Topics Cannabis
Cannabis Stock Movers For January 9, 2025
 
Via Benzinga
Topics Cannabis
Amplify To Liquidate Cannabis-Focused MJUS ETF As Regulatory Uncertainty Weighs On Sector
Amplify ETFs plans to liquidate MJUS, a cannabis-related ETF, due to regulatory issues. Other cannabis ETFs also struggling with DEA's indecisiveness. 
Via Benzinga
Topics Cannabis ETFs
DEA Accused Of Bias In Cannabis Rescheduling Hearings: Weed Stocks Plummeted In 2024 As Process Drags On
DEA judge orders agency to respond to allegations of opposing marijuana rescheduling and improper communication with opponents. Cannabis stocks declined in 2024 due to concerns about DEA review. 
Via Benzinga
Topics Cannabis
Surgeon General's Alcohol Cancer Warning And Dry January: This Cannabis Company Has You Covered
Just in time for Dry January, Curaleaf announced an expansion to the company's fast-acting Select Zero Proof Hemp THC Seltzers. 
Via Benzinga
Topics Cannabis
420 with CNW — NORML Analysis Shows at Least 35,000 Studies Were Done on Cannabis in the Last 10 Years
Via CannabisNewsWire
Topics Cannabis
US Marijuana Research is Witnessing an Evolving Landscape
Via CannabisNewsWire
Topics Cannabis
The Price Is Right: This Weed Real Estate Stock Proves Conservative Strategies Bring Returns
New Lake Capital Partners (OTC:NLCP), a real estate company focused on cannabis properties, offers an attractive investment with a 9.1% dividend yield, well above the return on 10-year government... 
Via Benzinga
Topics Cannabis
420 with CNW — Marijuana Prices Gradually Reduce as Ohio’s Legal Market Grows
Via CannabisNewsWire
Topics Cannabis
EXCLUSIVE: Drug Expert Dr. Carl Hart Slams Cannabis Prohibition Amid Hemp-THC Surge
Dr. Carl Hart discusses hemp THC, unregulated markets, and the need for federal cannabis legalization to reduce risks and protect consumers. 
Via Benzinga
Topics Cannabis
Why Cannabis Sales Are Down In Massachusetts And New Mexico: The Numbers Behind The Dip
Massachusetts' average revenue per dispensary dropped to $362k/month, down 8% year-over-year, in New Mexico sales went down 3% in November. 
Via Benzinga
Topics Cannabis
Europe Says Thanks But We'll Do It Ourselves - Canada Leads In Raw Cannabis Exports, Not Oil
While dried flower exports have flourished, the growth of Canada's cannabis extracts, including oils and vapes, has been more erratic. 
Via Benzinga
Topics Cannabis
Illinois Cannabis Sales Back On Track In October Hitting $142.3M After Slight September Dip
ollowing a drop in September cannabis sales numbers in Illinois, October figures totaled $142.3 million, a 4.2% increase sequentially, reported New Cannabis Ventures' Alan Brochstein. Cannabis sales... 
Via Benzinga
Topics Cannabis
Ho-Ho-Holy Smokes! Record Weed Sales Drive Dispensaries To Stock Smart This Holiday Season
Flower remained the top-selling form factor, accounting for 43% of total sales, followed by vape at 28%, and edibles. 
Via Benzinga
Curaleaf Holdings: Is This Cannabis Company A Buy Or Hold?
In this article, we analyze Curaleaf using technical indicators, focusing on key levels and potential mid-term strategies. Let's dive in. 
Via Benzinga
Topics Cannabis
Is MariMed A Safe Haven In The Wake Of Florida's Cannabis Legalization Defeat?
For investors, MariMed represents a fundamentally strong outlier, but industry-wide challenges remain a drag on stock performance. 
Via Benzinga
Topics Cannabis
Diversify Around And Find Out: Can Vegas Superstore And Florida Sales Boost This Weed Penny Stock?
Is this 40-cent cannabis stock undervalued? Zuanic & Associates dives into its growth potential and market prospects. 
Via Benzinga
Topics Cannabis
Cannabis Cuts Opioid Prescriptions By 53%, Utah Study Suggests
Discover how cannabis for pain management reduced opioid prescriptions by 53% in Utah, signaling new opportunities for medical markets. 
Via Benzinga
Topics Cannabis
Cannabis Stock Gainers And Losers From November 29, 2024
 
Via Benzinga
Topics Cannabis
Pharma-Grade Cannabis Could Hit Walgreens & CVS—But Can The Industry Survive The FDA?
As the formal review process for rescheduling cannabis unfolds, industry players are closely watching its potential to transform the sector. 
Via Benzinga
Topics Cannabis
Flora Growth Taps Europe's CBD Boom With $500K Czech-Slovak Partnership Renewal
 
Via Benzinga
Federal Policy Could Add $3 Billion To Cannabis Industry: On Track To Reach $55 Billion By 2030
According to LeafLink, over the next 2-3 years, 5,000 non-MSO retailers are projected to open in key states, increasing store counts by 70%. 
Via Benzinga
Topics Cannabis
80% Leverage, 5.5x EBITDA: Is Cresco The High-Risk, High-Reward Play Investors Need?
According to Z&A, its enterprise value (EV) to current sales ratio stands at 1.6x, lower than Curaleaf and Green Thumb, both at 2.2x. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.